Compound: xylometazoline
SMILES: N1=C(NCC1)Cc2c(cc(C(C)(C)C)cc2C)C
InChIKey: HUCJFAOMUPXHDK-UHFFFAOYSA-N
Synonyms: xylometazoline, 526-36-3, Xylomethazoline, Otriven, 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole, Xilometazolina, Xylometazolinum, Balminil, WPY40FTH8K, 2-(4-tert-Butyl-2,6-dimethylbenzyl)-2-imidazoline, 1H-Imidazole, 2-((4-(1,1-dimethylethyl)-2,6-dimethylphenyl)methyl)-4,5-dihydro-, DTXSID8046957, 1H-Imidazole, 2-[[4-(1,1-dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-, stas, Nasan, Otrivin Mentol, Nasentropfen AL, Nasenspray AL, 2-((4-tert-butyl-2,6-dimethylphenyl)methyl)-4,5-dihydro-1H-imidazole, NasenSpray ratiopharm, NasenTropfen ratiopharm, RefChem:58081, DTXCID6026957, 2-(4'-tert-butyl-2',6'-dimethylphenylmethyl)imidazoline, R01AA07, R01AB06, S01GA03, 208-390-6, Otrivin, Otrix, 2-(4-(tert-butyl)-2,6-dimethylbenzyl)-4,5-dihydro-1H-imidazole, Ba-11391, CHEMBL312448, 2-IMIDAZOLINE, 2-(4-tert-BUTYL-2,6-DIMETHYLBENZYL)-, Ba 11391; Otriven; Otrivin, Xylometazoline (INN), XYLOMETAZOLINE [INN], F1371-0282, 2-{[4-(tert-butyl)-2,6-dimethylphenyl]methyl}-2-imidazoline, Xylometazoline [INN:BAN], Xylometazolinum [INN-Latin], Xilometazolina [INN-Spanish], NCGC00016101-02, EINECS 208-390-6, UNII-WPY40FTH8K, Ba 11391, CAS-1218-35-5, BRN 0180524, Balminil (TN), Spectrum_000382, Prestwick0_000223, Prestwick1_000223, Prestwick2_000223, Prestwick3_000223, Spectrum2_000945, Spectrum3_000586, Spectrum4_000382, Spectrum5_001469, Lopac-X-6000, XYLOMETAZOLINE [MI], 2-[[4-(1,1-Dimethylethyl)-2,6-dimethylphenyl]methyl]-4,5-dihydro-1H-imidazole, Lopac0_001269, SCHEMBL34087, BSPBio_000265, BSPBio_002032, GTPL517, KBioGR_000903, KBioSS_000862, 5-23-07-00109 (Beilstein Handbook Reference), DivK1c_000158, XYLOMETAZOLINE [VANDF], SPBio_000910, SPBio_002186, BPBio1_000293, XYLOMETAZOLINE [WHO-DD], BDBM30703, CHEBI:10082, cid_5282386, HY-B0475A, KBio1_000158, KBio2_000862, KBio2_003430, KBio2_005998, KBio3_001532, NINDS_000158, HMS3604M22, HMS5085B13, SMSSF-0040298, 2-(4-tert-Butyl-2,6-dimethylbenzyl)-4,5-dihydro-1H-imidazole, EBC-26296, MFCD00242956, s5854, SBB038185, STK558658, 2-[(4-tert-butyl-2,6-dimethyl-phenyl)methyl]-4,5-dihydro-1H-imidazole, AKOS000115430, CCG-205342, DB06694, KS-5071, SDCCGSBI-0051235.P004, IDI1_000158, C4X-17232Oxymetazoline EP Impurity B, NCGC00016101-01, NCGC00016101-03, NCGC00016101-04, NCGC00016101-05, NCGC00016101-06, NCGC00016101-07, NCGC00016101-09, NCGC00016101-18, NCGC00024281-03, ST024781, SBI-0051235.P003, DB-052151, CS-0013861, NS00000479, EN300-02385, VU0239751-6, C07913, D08684, G78137, Q31030, AB00053567_11, AB00053567_12, L001171, 2-[(4-tert-butyl-2,6-xylyl)methyl]-2-imidazoline, BRD-K08356259-003-05-6, BRD-K08356259-003-15-5, BRD-K08356259-003-23-9, BRD-K08356259-003-24-7, 2-(4-tert-butyl-2,6-dimethyl-benzyl)-2-imidazoline;hydrochloride, 2-(4-tert-Butyl-2,6-dimethylbenzyl)-4,5-dihydro-1H-imidazole #, 2-[(4-t-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole, 2-[(4-t-butyl-2,6-dimethylphenyl)methyl]4,5dihydro-1H-imidazole, 2-[(4-tert-butyl-2,6-dimethyl-phenyl)methyl]-4,5-dihydro-1H-imidazole;hydrochloride, 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1H-imidazole;hydrochloride
Theoretical properties:
molecular_formula: C16H24N2
molecular_weight: 244.37 g/mol
exact_mass: 244.193948774 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 1
rotatable_bond_count: 3
heavy_atom_count: 18
topological_polar_surface_area: 24.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 317-329
Descriptions:
pubchem: Xylometazoline is an alkylbenzene.
chembl: XYLOMETAZOLINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.
wikipedia: Xylometazoline, also spelled xylomethazoline, is a medication used to reduce symptoms of nasal congestion, allergic rhinitis, and sinusitis. It is used directly in the nose as a spray or drops.
Side effects include trouble sleeping, irritation of the nose, nausea, nosebleed (3%), period pain (10%) and headache (3%). Long term use (> 10 days) is not recommended due to a rhinitis medicamentosa when stopped. Use is not recommended during pregnancy. Xylometazoline is in the decongestant and alpha-adrenergic agonist families of medication.
One study classified it with selectivity ratios in alpha 2 adrenergic receptors of 151 for a2A vs a2B, 4.5 a2A vs a2C, and 33.9 a2B vs a2C.  Making it a highly selective a2A agonist.
Xylometazoline was patented in 1956 and came into medical use in 1959. It is on the World Health Organization's List of Essential Medicines. Xylometazoline is available as a generic medication.